Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NovoGluten is a standardized clinical gluten product developed by Novoviah Pharmaceuticals for use in celiac disease clinical trials and gluten challenge studies. It is designed to provide consistent and credible gluten material to elicit and measure immune responses in patients with celiac disease. The product undergoes extensive testing for protein content, water, R5-ELISA, and microbiology, and is evaluated in stability studies under various storage conditions. It serves as a standardized challenge or diagnostic material rather than a therapeutic agent, helping researchers inform study design, statistical powering, and analysis for celiac disease research. The active ingredient consists of gluten protein derived from wheat, barley, and/or rye.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NovoGluten.